Repositioning Candidate Details
| Candidate ID: | R0876 |
| Source ID: | DB05805 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | NS-2359 |
| Synonyms: | -- |
| Molecular Formula: | C16H21Cl2NO |
| SMILES: | COC[C@H]1[C@H]2CC[C@@H](C[C@@H]1C1=CC(Cl)=C(Cl)C=C1)N2C |
| Structure: |
|
| DrugBank Description: | NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. Enhancing the function of the three neurotransmitters serotonin, noradrenalin and dopamine, NS2359 has a desired "triple-mode-of-action". This mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market. |
| CAS Number: | 195875-68-4 |
| Molecular Weight: | 314.25 |
| DrugBank Indication: | Investigated for use/treatment in addictions, attention deficit/hyperactivity disorder (ADHD), and depression. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | NS2359 has a triple mode of action, inhibiting neuronal reuptake of the three neurotransmitters serotonin, noradrenaline and dopamine, all of which play an important role in the development of depression. NS2359 also increases release of the neurotransmitter acetylcholine. This mode of action is expected to produce a better and faster reduction of the symptoms associated with depression. This rationale has been confirmed in independent studies in which existing anti-depressants affecting serotonin have been combined with drugs that affect noradrenaline/dopamine. Drugs with this triple mode of action are expected to become the future standard in the treatment of depression. |
| Targets: | -- |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|